Simvastatin: Present and future perspectives

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 13, 2007, Pages 2159-2127

  Robinson, Jennifer G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cardiovascular prevention; Cardiovascular risk; HMG CoA reductase inhibitor; Simvastatin; Statins

Indexed keywords

AMIODARONE; ATORVASTATIN; CARBAMAZEPINE; CERIVASTATIN; CLARITHROMYCIN; CYANOCOBALAMIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DANAZOL; ERYTHROMYCIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; FLUINDOSTATIN; FOLIC ACID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MK 0524; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; PLACEBO; PRAVASTATIN; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACANTHOSIS NIGRICANS; ARTICLE; ATHEROSCLEROSIS; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEMATURIA; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERURICEMIA; KIDNEY FAILURE; LIPOPHILICITY; LIVER FAILURE; MONOTHERAPY; MORTALITY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NONHUMAN; PEPTIC ULCER; PHARMACODYNAMICS; PROTEINURIA; RECOMMENDED DRUG DOSE; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; ANIMAL; BLOOD; CHEMISTRY; FORECASTING; HYPERLIPIDEMIA; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FORECASTING; HUMANS; HYPERLIPIDEMIAS; SIMVASTATIN;

EID: 34548638774     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.13.2159     Document Type: Article

References (108)

1. STRONG K, MATHERS C, LEEDER S, BEAGLEHOLE R: Preventing chronic diseases: how many lives can we save? Lancet (2005) 366:1578-1582
2. THOM T, HAASE N, ROSAMOND W et al.: Heart disease and stroke statistics - 2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation (2006) 113:E85-E151.
3. SHOOB HD, CROFT JB, LABARTHE DR: Impact of baby boomers on hospitalizations for coronary heart disease and stroke in the United States. Prev. Med. (2007) 44:447-451.
4. ROTHWELL P, COULL A, SILVER L et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study) Lancet (2005) 366:1773-1783.
5. CHOLESTEROL TREATMENT TRIALISTS' (CTT) COLLABORATORS: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 366:1267-1278.
6. NATIONAL CHOLESTEROL EDUCATION PANEL: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III) final report. Circulation (2002) 106:3143-3421.
7. DE BACKER G, AMBROSIONI E, BORCH-JOHNSEN K et al.: European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur. J. Cardiovasc. Prev. Rehab. (2003) 10:S1-S78.
8. GENEST J, FROHLICH J, FODOR G, MCPHERSON R: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ (2003) 169:921-924.
9. CANNON CP, STEINBERG BA, MURPHY SA et al.: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol. (2006) 48:438-445.
10. GRUNDY SM, CLEEMAN JI, MERZ CNB et al.: Implications of recent clinical trials for the National cholesterol education program adult treatment Panel III guidelines. Circulation (2004) 110:227-239.
11. SMITH JSC, ALLEN J, BLAIR SN et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National heart, lung, and blood Institute. J. Am. Coll. Cardiol. (2006) 47:2130-2139.
12. NASH DB, NASH SA: Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy. Am. J. Cardiol. (2004) 94:35-39.
13. HOFFMAN WF, ALBERTS AW, ANDERSON PS et al.: 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side-chain ester derivatives of mevinolin. J. Med. Chem. (1986) 29:849-852.
14. GRUNDY S: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. (1988) 319:24-33.
15. BILHEIMER DW, GRUNDY SM, BROWN MS, GOLDSTEIN JL: Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. Atherosclerosis Suppl. (2004) 5:61-65.
16. BROWN M, GOLDSTEIN J: Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J. Clin. Invest. (1983) 72:743-747.
17. PRUEKSARITANONT T, GORHAM LM, MA B et al.: In vitro metabolism of simvastatin in humans [sbt]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. (1997) 25:1191-1199.
18. PRUEKSARITANONT T, SUBRAMANIAN R, FANG X et al.: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. (2002) 30:505-512.
19. GOOSEN TC, BAUMAN JN, DAVIS JA et al.: Atorvastatin glucuronidation is minimally and non-selectively inhibited by the fibrates gemfibrozil, fenofibrate and fenofibric acid. Drug Metab. Dispos. (2007) 35(8):1315-1324.
20. SPENCE J, MUNOZ C, HENDRICKS L et al.: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. (1995) 76:A80-A83.
21. PRUEKSARITANONT T, TANG C, QIU Y et al.: Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. (2002) 30:1280-1287.
22. KIM K-A, PARK P-W, LEE O-J et al.: Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. (2007) 47:87-93.
23. PASANEN M, NEUVONEN M, NEUVONEN P, NIEMI M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genom. (2006) 16:873-879.
24. VICKERS S, DUNCAN CA, VYAS KP et al.: In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. (1990) 18:476-483.
25. WALLACE A, CHINN D, RUBIN G: Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ (2003) 327:788.
26. CHENG H, ROGERS J, SWEANY A et al.: Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm. Res. (1992) 9:1629-1633.
27. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7-22.
28. BALLANTYNE CM, BLAZING MA, HUNNINGHAKE DB et al.: Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the comparative HDL efficacy and safety study (CHESS). Am. Heart J. (2003) 146:862-869.
29. ROGERS SL, MAGLIANO DJ, LEVISON DB et al.: A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin. Ther. (2007) 29:242-252.
30. SIMOONS ML, SAELMAN JPM: Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet (1994) 344:633-638.
31. BROWN BG, ZHAO X-Q, CHAIT A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. (2001) 345:1583-1592.
32. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY G: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383-1389.
33. PEDERSEN TR: Coronary artery disease: the Scandinavian Simvastatin Survival Study Experience. Am. J. Cardiol. (1998) 82:53-56.
34. PYORALA K, PEDERSEN TR, KJEKSHUS J et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care (1997) 20:614-620.
35. MIETTINEN TA, PYORALA K, OLSSON AG et al.: Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation (1997) 96:4211-4218.
36. PYORALA K, BALLANTYNE CM, GUMBINER B et al.: Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care (2004) 27:1735-1740.
37. HEART PROTECTION STUDY COLLABORATIVE G: The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med. (2005) 3:6.
38. HEART PROTECTION STUDY COLLABORATIVE GROUP: Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg. (2007) 45:645-654; discussion 653-654.
39. HEART PROTECTION STUDY COLLABORATIVE G: N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J. Am. Coll. Cardiol. (2007) 49:311-319.
40. HEART PROTECTION STUDY COLLABORATIVE GROUP: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk complications. Lancet (2004) 363:757-767.
41. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361:2005-2016.
42. MACMAHON M, KIRKPATRICK C, CUMMINGS C et al.: A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. (2000) 10:195-203.
43. PACKARD C: Improving outcomes through statin therapy - a review of ongoing trials. Eur. Heart J. Suppl. (2004) 6:A28-A31.
44. ROBINSON J, DAVIDSON M: Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev. Cardiovasc. Ther. (2006) 4:461-476.
45. BALLANTYNE CM, ABATE N, YUAN Z et al.: Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the vytorin versus atorvastatin (VYVA) study. Am. Heart J. (2005) 149:464-473.
46. CATAPANO AL, DAVIDSON MH, BALLANTYNE CM et al.: Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients Curr. Med. Res. Opin (2006) 22:2041-2053.
47. DAVIDSON MH, MACCUBBIN D, STEPANAVAGE M et al.: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am. J. Cardiol. (2006) 97:223-228.
48. ROSSEBO AB, PEDERSEN TR, ALLEN C et al.: Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am. J. Cardiol. (2007) 99:970-973.
49. BAIGENT C, LANDRY M: Study of heart and renal protection (SHARP). Kidney Int. (2003) 63:S207-S210.
50. WOLFE ML, VARTANIAN SF, ROSS JL et al.: Safety and effectiveness of niaspan when added sequentially to a statin for treatment of dyslipidemia. Am. J. Cardiol. (2001) 87:476-479.
51. MEYERS CD, LIU P, KAMANNA VS, KASHYAP ML: Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis (2007) 192:253-258.
52. CHENG K, WU T-J, WU KK et al.: Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. USA (2006) 103:6682-6687.
53. MCGOVERN M: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br. J. Diabetes Vasc. Dis (2004) 4:78-85.
54. CANNER PL, FURBERG CD, MCGOVERN ME: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. (2006) 97:477-479.
55. ALSHEIKH-ALI AA, KARAS RH: Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States food and drug administration adverse event reporting system). Am. J. Cardiol. (2007) 99:379-381.
56. GUYTON JR, BAYS HE: Safety considerations with niacin therapy. Am. J. Cardiol. (2007) 99:S22-S31.
57. THOMPSON PD, CLARKSON PM, ROSENSON RS: An assessment of statin safety by muscle experts. Am. J. Cardiol. (2006) 97:S69-S76.
58. GRAHAM DJ, STAFFA JA, SHATIN D et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 292:2585-2590.
59. KANTOLA T, KIVISTO KT, NEUVONEN PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. (1998) 64:177-182.
60. JACOBSON TA: Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. (2004) 94:1140-1146.
61. NEUVONEN PJ, NIEMI M, BACKMAN JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. (2006) 80:565-581.
62. MOLDEN E, ANDERSSON K: Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. Pharmacotherapy (2007) 27:603-607.
63. RICAURTE B, GUIRGUIS A, TAYLOR HC, ZABRISKIE D: Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann. Pharmacother. (2006) 40:753-757.
64. JACOB SS, JACOB S, WILLIAMS C, DEEG MA: Simvastatin, fenofibrate, and rhabdomyolysis. Diabetes Care (2005) 28:1258.
65. MORO H, TSUKADA H, TANUMA A et al.: Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS (2004) 18:687-690.
66. ROTEN L, SCHOENENBERGER RA, KRAHENBUHL S, SCHLIENGER RG: Rhabdomyolysis in association with simvastatin and amiodarone. Ann. Pharmacother. (2004) 38:978-981.
67. ANDREOU E, LEDGERS: Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can. J. Clin. Pharmacol. (2003) 10:172-174.
68. HARE C, VU M, GRUNFELD C, LAMPIRIS H: Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin. Infect. Dis. (2002) 35:E111-E112.
69. CHENG CH, MILLER C, LOWE C, PEARSON VE: Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am. J. Health Syst. Pharm. (2002) 59:728-730.
70. PECES R, POBES A: Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron (2001) 89:117-118.
71. ARNADOTTIR M, ERIKSSON L, THYSELL H, KARKAS J: Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron (1993) 65:410-413.
72. VAN PUIJENBROEK E, DU BUF-VEREIJKEN P, SPOOREN P, VAN DOORMAAL J: Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J. Intern. Med. (1996) 240:403-404.
73. DREIER JP, ENDRES M: Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology (2004) 62:670.
74. SCHMASSMANN-SUHIJAR D, BULLINGHAM R, GASSERR et al.: Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet (1998) 351:1929-1930.
75. BOTTORFF MB: Statin safety and drug interactions: clinical implications. Am. J. Cardiol. (2006) 97:S27-S31.
76. BECQUEMONT L, NEUVONEN M, VERSTUYFT C et al.: Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin. Pharmacol. Ther. (2007) 81:679-684.
77. PRUEKSARITANONT T, ZHAO JJ, MA B et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. (2002) 301:1042-1051.
78. KARNIK NS, MALDONADO JR: Antidepressant and statin Interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics (2005) 46:565-568.
79. WEBBER MA, MAHMUD W, LIGHTFOOT JD, SHEKHAR A: Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J. Psychopharmacol. (2004) 18:432-434.
80. THE DAD STUDY GROUP: Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. (2007) 356:1723-1735.
81. BELLOSTA S, PAOLETTI R, CORSINI A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation (2004) 109:III-50-57.
82. NEUVONEN P, KANTOLA T, KIVISTO K: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. (1998) 63:332-341.
83. LILJA JJ, NEUVONEN M, NEUVONEN PJ: Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastattn. Br. J. Clin. Pharmacol. (2004) 58:56-60.
84. LILJA JJ, KIVISTO KT, NEUVONEN PJ: Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin[ast]. Clin. Pharmacol. Ther. (2000) 68:384-390.
85. LILJA J, KIVISTO K, NEUVONEN P: Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. (1998) 64:477-483.
86. EDWARDS DJ, BERNIER SM: Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci. (1996) 59: 1025-1030.
87. TRANSON C, LEEMANN T, DAYER P: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. (1996) 50:209-215.
88. COHEN D, ANANIA F, CHALASANI N: An assessment of statin safety by hepatologists. Am. J. Cardiol. (2006) 97:S77-S81.
89. DAVIDSON M, ROBINSON JG: Safety of aggressive lipid management. J. Am. Coll. Cardiol. (2007) 49:1753-1762.
90. BRASS LM, ALBERTS MJ, SPARKS L: An assessment of statin safety by neurologists. Am. J. Cardiol. (2006) 97:S86-S88.
91. KASISKE BL, WANNER C, O'NEILL WC: An assessment of statin safety by nephrologists. Am. J. Cardiol. (2006) 97:S82-S85.
92. JACOBSON TA: Statin safety lessons from new drug applications for marketed statins. Am. J. Cardiol. (2006) 97:S44-S51.
93. SHEPHERD J, VIDT D, MILLER E et al.: Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology (2007) 107:433-443.
94. DOUGLAS K, O'MALLEY PG, JACKSON JL: Meta-analysis: the effect of statins on albuminuria. Ann. Intern. Med. (2006) 145:117-124.
95. DALE KM, COLEMAN CI, HENYAN NN et al.: Statins and cancer risk: a meta-analysis. JAMA (2006) 295:74-80.
96. STRANDBERG T, PYORALA K, COOK TJ et al.: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 364:771-777.
97. BULBULIA R, BOWMAN L, WAILENDAZUS K et al.: MRC/BHF heart protection study (HPS): mortality, cancer incidence and major vascular evetns during 4 years post-trial follow-up of HPS [abstract] Presented at the American College of Cardiology 56th Annual Scientific Session. J. Am. Coll. Cardiol. (2007) 49:A394A.
98. CHAN PS, NALLAMOTHU BK, GURM HS et al.: Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation (2007) 115:2398-2409.
99. HEART PROTECTION STUDY COLLABORATIVE GROUP: Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ (2006) 333:1145. doi:10.1136/bmj.38993.731725.BE
100. ROBINSON JG, STONE NJ: Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am. J. Cardiol. (2006) 98:1405-1408.
101. TALL AR, YVAN-CHARVET L, WANG N: The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. (2007) 27:257-260.
102. NISSEN SE, TARDIF J-C, NICHOLLS SJ et al.: Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. (2007) 356:1304-1316.
103. KASTELEIN JJP, VAN LEUVEN SI, BURGESS L et al.: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. (2007) 352:1425-1435.
104. ROBINSON JG, MAHESHWARI N: A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am. J. Cardiol. (2005) 95:373-378.
105. HOLMES HM, HAYLEY DC, ALEXANDER GC, SACHS GA: Reconsidering medication appropriateness for patients late in life. Arch. Intern. Med. (2006) 166:605-609.
106. ROBINSON JG, BAKRIS G,TORNER J et al.: Is it time for a cardiovascular primary prevention trial in the elderly? Stroke (2007) 38:441-450.
107. GORELICK PB: Uncertainty of management of blood pressure and lipids in the elderly: time for a primary prevention trial. Stroke (2007) 38:212-213.
108. BROOKHART MA, PATRICK AR, SCHNEEWEISS S et al.: Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch. Intern. Med. (2007) 167:847-852.